

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA BIOTECH SERVICES HOLDINGS LIMITED**

**中國生物科技服務控股有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

### **EXTENSION OF MEMORANDUM OF UNDERSTANDING**

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) on a voluntary basis to keep shareholders and potential investors of the Company informed of the latest business development of the Group.

References are made to the announcement and circular (the “**Circular**”) of the Company dated 23 June 2022 and 22 August 2022, respectively. Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

As disclosed in the Circular, the Company, Pengbo (Hainan) and SHI entered into the MOU in relation to the supply of the BNCT Parts and the provision of the O&M Service to Pengbo (Hainan) by SHI. Pursuant to the MOU, the Term of the MOU shall commence on the date of the MOU and shall remain in effective until either (i) 31 December 2022; or (ii) the Definitive Contracts for both the Proposed Supply of the BNCT Parts and the Proposed Provision of O&M Service are concluded and executed, whichever comes first.

As additional time is required for the Company, Pengbo (Hainan) and SHI to negotiate and agree on the terms of the Definitive Contracts, on 28 December 2022 (after trading hours), the Company, Pengbo (Hainan) and SHI entered into the addendum (“**Addendum**”) to the MOU to extend the Term of the MOU (the “**Extended Term**”). Pursuant to the Addendum, the Extended Term shall commence on the date of the Addendum and shall remain in effective until either (i) 31 January 2023; or (ii) the Definitive Contracts for both the Proposed Supply of the BNCT Parts and the Proposed Provision of O&M Service are concluded and executed, whichever comes first.

Save for the above, all other terms and conditions of the MOU shall remain unchanged and be in full force and effect in its original terms.

By order of the Board  
**China Biotech Services Holdings Limited**  
**Liu Xiaolin**  
*Chairman and Executive Director*

Hong Kong, 28 December 2022

*As at the date of this announcement, the board of Directors comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from the date of its publication and on the website of the Company at [www.cbshhk.com](http://www.cbshhk.com).*